Popular anti-aging drug cocktail strips myelin from mouse brains - worse in younger animals

The drug combination was supposed to make things younger. Instead, it made brain cells younger in the worst possible way.

Dasatinib plus quercetin (D+Q) is one of the most studied senolytic cocktails in anti-aging research - a pair of drugs designed to eliminate senescent cells, the aged and damaged cells that accumulate in the body and drive inflammation. Dozens of studies have shown it reduces age-related symptoms. It is being tested for conditions from Type 2 diabetes to Alzheimer's disease. Some people in the longevity community take it off-label, though doctors advise against it.

Very few studies had looked at what D+Q does to the brain. Now, researchers at the University of Connecticut have, and the results are alarming. Published March 16 in PNAS, their study found that D+Q at standard research doses caused severe myelin damage in mice - and the damage was worse in younger animals than in older ones.

The insulation disappears

Myelin is the fatty sheath that insulates nerve fibers, enabling fast and efficient signal transmission throughout the brain and nervous system. When myelin degrades, nerves malfunction. People develop numbness, pain, cognitive problems, and difficulty walking. Myelin loss is the central pathology of multiple sclerosis.

The Connecticut team, led by immunologist Stephen Crocker, treated mice with D+Q at doses commonly used in aging research and examined their brains. Healthy mouse brains show myelin as dark rings surrounding lighter axons (nerve fibers). In treated mice, those dark rings were dramatically reduced. The corpus callosum - the massive fiber bundle connecting the brain's two hemispheres, critical for coordination, cognition, and information processing - essentially disappeared.

This kind of damage is known to occur in some human chemotherapy patients, where it causes the collection of symptoms popularly called "chemo brain." Finding it caused by a drug cocktail that people voluntarily take for longevity is a different category of concern.

Cells regressed, not died

When the researchers examined the damaged tissue closely, they found something unexpected. The oligodendrocytes - the brain cells responsible for producing and maintaining myelin - had not died. They had reverted to an immature, juvenile form of themselves. The cells were alive but had shed their adult function, losing the ability to produce the myelin sheath that nerves depend on.

The researchers suspect the drugs starve the cells of energy. "We suspect the drugs are choking off energy the cells need, and the cells respond by reducing complexity, reverting to a younger state, but less functional," Crocker said.

Intriguingly, these regressed cells closely resemble a distinct population of cells found in the brains of people with multiple sclerosis. This parallel suggests that in MS, myelinating cells may be coming under similar metabolic stress and reverting to a juvenile state rather than dying outright. If that is the case, those cells might potentially be coaxed back into maturity - a possibility the team is now investigating.

Younger mice hit harder

The study tested both young mice (6 to 9 months) and old mice (22 months), as well as oligodendrocytes cultured in the lab. The damage was present in both age groups but was markedly worse in the younger animals - a counterintuitive finding for a drug combination designed to target aging.

The original research idea, pursued by graduate students Evan Lombardo and Robert Pijewski in Crocker's lab, was to see if D+Q could rejuvenate the brains of people with MS by clearing senescent cells. The expectation was that removing aged, dysfunctional cells would allow fresh myelin production. The reality was the opposite.

From cautionary finding to MS insight

The practical implications run in two directions. First, the findings should give pause to anyone prescribing or using D+Q prophylactically. The brain effects at standard doses are severe, and the greater vulnerability of younger tissue is particularly concerning given the demographic most likely to pursue anti-aging interventions.

Second, and more optimistically, the discovery that oligodendrocytes regress rather than die offers a potential therapeutic window for MS. If the cells can be pushed back into a mature, myelinating state, brain repair might be possible. Crocker's team is now working on exactly this question: "If we can mimic this, we have an amazing opportunity to see if the cells can recover and repair the brain."

The study was conducted in mice, and direct translation to human brain effects requires caution. But the doses used mirror those in standard aging research protocols, and the mechanisms of myelin maintenance are conserved across mammals. For a drug combination already being taken by some people without prescription, the findings raise urgent questions about neurological monitoring.